Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Primary Progressive Aphasia With Suspected Alzheimer's Disease
Interventions
18F-AV-1451, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
20 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Neuroimaging Study

NCT03618186
Conditions
Cognitive Impairment
Interventions
Tau PET scan
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Recruiting No phase listed Observational Accepts healthy volunteers

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Clinical tau PET, Clinical amyloid test, Research blood collection, Cognitive assessments
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting

NCT04309500
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
Personalized DAT Risk Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Alzheimer's Disease
Interventions
LY3202626, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
49
States / cities
Irvine, California • Sacramento, California • San Diego, California + 40 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tau PET Imaging in Opioid Use Disorder

NCT05651516
Conditions
Opioid-Related Disorders
Interventions
18F-PI-2620 PET/CT
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Results available

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713
Conditions
Frontotemporal Dementia
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Dallas, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Completed Phase 3 Interventional Results available

18F-AV-1451 Autopsy Study

NCT02516046
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Los Gatos, California • Newport Beach, California + 23 more
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

NCT04104659
Conditions
Alzheimer Disease
Interventions
MK 6240
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Withdrawn Not applicable Interventional Accepts healthy volunteers

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

NCT03641768
Conditions
Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Completed Not applicable Interventional Results available

Effect of Modulating Gamma Oscillations Using tACS

NCT03412604
Conditions
Alzheimer Disease
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Brain Imaging, Whole Body Imaging
Interventions
18F-FDG, 18F-AV1451, Siemens E7 Reconstruction Tool
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Alzheimer Disease, Cognitive Decline
Interventions
[18F]AV-1451, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Neil M Rofsky, MD, MHA
Other
Eligibility
38 Years to 96 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Completed No phase listed Observational Results available

Health & Aging Brain Study: Health Disparities TAU Project

NCT04324541
Conditions
Brain Aging in Mexican Americans
Interventions
PET scan of the brain with Flortaucipir
Diagnostic Test
Lead sponsor
Sid E. O'Bryant
Other
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers
Interventions
[18F]APN-1607
Drug
Lead sponsor
APRINOIA Therapeutics, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Not listed No phase listed Observational Accepts healthy volunteers

Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

NCT00966017
Conditions
Down Syndrome, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
45 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California